|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, December 24, 2018 ) This report provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.
GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.
Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.
Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.
Get Sample Copy of this Report@ https://www.orbisresearch.com/contacts/request-sample/2412246
Scope:
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy:
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Make an Inquiry before Buying@ https://www.orbisresearch.com/contacts/enquiry-before-buying/2412246
Key Players:
AbbVie Inc
AbGenomics International Inc
Alexion Pharmaceuticals Inc
AnaptysBio Inc
Angion Biomedica Corp
apceth Biopharma GmbH
Aptevo Therapeutics Inc
Astellas Pharma Inc
Athersys Inc
Balmes Transplantation SAS
Bellicum Pharmaceuticals Inc
Biogen Inc
Bioverativ Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Catalyst Biosciences Inc
Cell2B Advanced Therapeutics SA
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cynata Therapeutics Ltd
Cytodyn Inc
Dompe Farmaceutici SpA
Elsalys Biotech SA
enGene Inc
Enlivex Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Generon (Shanghai) Corp Ltd
Gilead Sciences Inc
GlaxoSmithKline Plc
Hansa Medical AB
Idogen AB
Incyte Corp
Inspyr Therapeutics Inc
ITB-Med AB
Jazz Pharmaceuticals Plc
Kadmon Corp LLC
Kamada Ltd
Kiadis Pharma NV
Kidney Transplant Rejection
Kymab Ltd
Kyowa Hakko Kirin Co Ltd
LG Chem Ltd
Liver Transplant Rejection
MaaT Pharma
Magenta Therapeutics Inc
MallInckrodt Plc
Medicenna Therapeutics Corp
Mesoblast Ltd
Millennium Pharmaceuticals Inc
Noorik Biopharmaceuticals AG
OncoImmune Inc
Opsona Therapeutics Ltd
Pfizer Inc
Pharming Group NV
Pluristem Therapeutics Inc
Prolong Pharmaceuticals LLC
Quark Pharmaceuticals Inc
RedHill Biopharma Ltd
REGiMMUNE Corp
Sanofi
Seattle Genetics Inc
Seres Therapeutics Inc
Shire Plc
Sublimity Therapeutics Ltd
Syndax Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TC BioPharm Ltd
TolerogenixX GmbH
United BioPharma Inc
Vault Pharma Inc
VBI Vaccines Inc
Veloxis Pharmaceuticals A/S
Visterra Inc
Xenikos BV
XL-protein GmbH
Zai Lab Ltd
Get More Information about this Report@ https://www.orbisresearch.com/reports/index/transplant-complications-drug-development-pipeline-review-2018
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
